gammaCore® Receives FDA Clearance for the Acute Treatment of Pain Associated with Migraine Headache in Adult Patients
Basking Ridge, NJ, January 29, 2018 – electroCore, LLC (electroCore), a commercial-stage bioelectronic medicine company, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for an expanded label for gammaCore® (nVNS) as an acute treatment of p...
Investment to fund commercialization of gammaCore® and further clinical development of nVNS Basking Ridge, NJ, November 29, 2017 – electroCore, ...
PRESTO demonstrates clinical benefit of gammaCore in the acute treatment of migraine compared to sham Basking Ridge, NJ, September 11, 2017 – electr...
Nick Colucci Brings Invaluable Healthcare Communications Expertise to Enhance electroCore’s Continued Growth Basking Ridge, NJ, August 29, 2017 – ...
electroCore launches gammaCore Patient Registry (GPR) to provide access to hand-held, easy-to-use device for the acute treatment of pain associated wi...
Upcoming events centered around disorders that can be treated with nVNS
As between you and electroCore, LLC, electroCore, LLC is and shall remain the sole and exclusive owner of material provided in the Media Center.
How to use gammaCore
gammaCore Device Application
Alexandra Peterson, GCI Health